Home / Market News / $CAPR
fiscal.ai Corporate Catalyst Impact 85/100 ● negative

Capricor Therapeutics Reports Third Quarter 2026 Financial Results

Nov 11, 2026, 2:09 PM UTC · Primary ticker $CAPR

Capricor Therapeutics reported a significantly wider net loss in Q3 2026 compared to the prior year, driven by increased operating expenses related to pre-commercial and manufacturing scale-up activities. This financial performance, coupled with the BLA amendment submission, indicates the company is progressing towards commercialization but at a higher cost, which could pressure short-term investor sentiment.

Capricor Therapeutics announced a net loss of $42.7 million for Q3 2026, a substantial increase from $24.6 million in Q3 2025. This wider loss is primarily attributed to a significant rise in operating expenses, up to $44.7 million from $26.3 million, driven by pre-commercial and manufacturing scale-up activities for Deramiocel. This indicates the company is investing heavily in preparing for potential market entry, which is a necessary step but also a cash-intensive one. The submission of HOPE-3 OLE data as a major amendment to its BLA is a positive clinical development, but the increased burn rate could concern investors in the short term, potentially leading to downward pressure on the stock. Long-term implications depend on the successful approval and commercialization of Deramiocel, which would justify the current expenditures. Traders should monitor cash burn rates and upcoming regulatory decisions closely.

$CAPR negative Wider net loss, increased expenses
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.